Share on StockTwits

AstraZeneca plc (ADR) (NYSE:AZN) posted its quarterly earnings results on Thursday. The company reported $1.17 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.23 by $0.06, AnalystRatings.NET reports. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.32 billion. During the same quarter last year, the company posted $1.41 earnings per share. AstraZeneca plc (ADR)’s revenue was up .5% compared to the same quarter last year.

Shares of AstraZeneca plc (NYSE:AZN) traded up 2.98% on Thursday, hitting $69.80. 2,673,126 shares of the company’s stock traded hands. AstraZeneca plc has a 52-week low of $46.87 and a 52-week high of $69.65. The stock has a 50-day moving average of $65.17 and a 200-day moving average of $60.17. The company has a market cap of $87.750 billion and a price-to-earnings ratio of 33.23. AstraZeneca plc (ADR) also saw unusually large options trading on Monday. Stock traders bought 8,863 call options on the company. This represents an increase of 1,011% compared to the average volume of 798 call options.

Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc (ADR) in a research note on Tuesday. On a related note, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc (ADR) in a research note on Tuesday. Finally, analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca plc (ADR) in a research note on Tuesday. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $63.00.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.